Filing Flows › Arcus Biosciences (RCUS) › Q1 2025
Arcus Biosciences (RCUS) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 6, 2025
Arcus Biosciences (RCUS) reported revenue of $28.0M for the first quarter 2025 (Q1 2025), -81% from a year earlier and +8% from the quarter before. Operating margin was -435.7%, net loss $112M (400.0% of revenue).
Arcus Biosciences, Q1 2025: revenue $28.0M (-81% year over year), operating margin -435.7%, net loss $112M, operating cash flow −$132M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $28.0M | +8% | -81% |
| Operating profit | −$122M | — | — |
| Net earnings | −$112M | — | — |
| Operating cash flow | −$132M | — | — |
What changed
Revenue was $28.0M in Q1 2025, down 81% year over year and up 8% from the previous quarter. License and Development Services Revenue was the largest line at 71% of revenue. License and Development Services Revenue lost $115.0M year over year (down 85%), 98% of the total change.
Operating costs exceeded revenue by $122.0M, an operating margin of -435.7%. Total costs fell 7% while revenue fell 81%. The fastest-growing cost line was Research & development (+12%). The quarter ended with a net loss of $112.0M, wider than the previous quarter's $94.0M loss.
Operating cash flow was −$132.0M. Non-cash charges added back $3.0M of depreciation and amortization and $16.0M of share-based compensation. Working capital and other items used $39.0M. Capital expenditures of $1.0M exceeded it, leaving free cash flow of −$133.0M.
Questions
What was Arcus Biosciences' revenue in the first quarter 2025?
Arcus Biosciences (RCUS) reported revenue of $28.0M for the first quarter 2025 (Q1 2025), -81% from a year earlier and +8% from the quarter before.
Was Arcus Biosciences profitable in the first quarter 2025?
Operating loss was $122M (-435.7% of revenue) and net loss $112M.
Source: Arcus Biosciences 10-Q on SEC EDGAR.